Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.
05 juin 2017 11h00 HE
|
Cornerstone Pharmaceuticals
Newark, NJ, June 05, 2017 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today announced that it is changing its corporate name to...
Cornerstone Pharmaceuticals to Present at the BioNJ 7th Annual BioPartnering Conference, May 23, 2017
22 mai 2017 14h00 HE
|
Cornerstone Pharmaceuticals
Cranbury, NJ, May 22, 2017 (GLOBE NEWSWIRE) -- Information on Cornerstone's upcoming presentation at this prestigious industry conference provided below: WHAT: In partnership with J.P....
The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
09 mai 2017 11h15 HE
|
Cornerstone Pharmaceuticals
Cranbury, NJ, May 09, 2017 (GLOBE NEWSWIRE) -- Cranbury, N.J., May 09, 2017 --(GlobeNewswire)-- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today...
Cornerstone Pharmaceuticals Receives Funding Through New Jersey's Technology Business Tax Certificate Transfer Program
21 janv. 2015 13h22 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, today announced that it...
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer
12 janv. 2015 10h38 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, today announced the...
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma
05 déc. 2014 08h30 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch
13 nov. 2014 12h28 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today...
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting
06 nov. 2014 09h52 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non-Hodgkin's Lymphoma
21 oct. 2014 12h13 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer
09 oct. 2014 13h33 HE
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...